"Statins should remain the first-line therapy for lowering cholesterol and reducing the risk of cardiovascular disease, but if they cannot be tolerated, nonstatin therapies may be just as beneficial. This is the conclusion of a new study published in JAMA." -MNT http://ift.tt/1VMjaZw
from Rajesh Harrykissoon, MD
